Viimased lisandused - Age-Related Macular Degeneration - Wet
|
Conversion to Wet AMD after Izervayvaatamisi: 3483 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3983 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3183 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 4583 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3583 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 2883 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3983 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3383 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3883 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3183 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3283 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 2683 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3883 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3383 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 2883 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3283 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Conversion to Wet AMD after Izervayvaatamisi: 3083 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentmärts 15, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 5785 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2985 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4185 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4085 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2785 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3085 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4085 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4285 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3385 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3385 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2985 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2285 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3285 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2685 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2785 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3785 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3085 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2885 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3785 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4385 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3385 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3685 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3585 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 4085 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3985 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 2285 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3885 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3685 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Peripapillary CNVM No Treatmentvaatamisi: 3385 year old with peripapillary CNVM watched for many years.veebr 18, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4287 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 5087 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 3787 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 5487 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4387 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4887 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4587 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4787 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4187 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 3887 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 5287 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4287 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 5287 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4587 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4387 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4887 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 4387 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vaatamisi: 5687 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400jaan 11, 2026
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 15983 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 14883 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 13883 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 13983 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 12783 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 14483 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 14983 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 13483 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 12483 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 15583 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 13183 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 13183 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 10183 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 9883 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 8383 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 9383 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 8383 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 7683 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvaatamisi: 10883 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTveebr 12, 2025
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 9977 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 10477 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8077 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 9177 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8877 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8277 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 7377 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 9077 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8777 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 10877 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 10177 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 9077 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8377 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 8777 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 11477 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 6877 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvaatamisi: 10077 year old female with mild vision loss - 20/32 - responded to Avastindets 19, 2024
|
|
|
|
